A5032895748- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Sarcoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Soft tissue tumor case studies
- Health Systems, Economic Evaluations, Quality of Life
- Viral-associated cancers and disorders
- Gastrointestinal Tumor Research and Treatment
- Tumors and Oncological Cases
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Cancer Diagnosis and Treatment
- Polyomavirus and related diseases
- Urologic and reproductive health conditions
- Cancer Immunotherapy and Biomarkers
- Palliative Care and End-of-Life Issues
- Economic and Financial Impacts of Cancer
- Pharmaceutical Practices and Patient Outcomes
Friedrich-Alexander-Universität Erlangen-Nürnberg
2013-2025
Universitätsklinikum Erlangen
2013-2025
Comprehensive Cancer Center Erlangen
2021-2025
Zentrum für Psychiatrie Emmendingen
2024
Bayer (Germany)
2020
University of Regensburg
1997-2008
UPMC Hillman Cancer Center
2000-2002
University Hospital Regensburg
2000
Abstract Although tumor-specific CD8 T-cell responses often develop in cancer patients, they rarely result tumor eradication. We aimed at studying directly the functional efficacy of T cells site immune attack. Tumor lesions lymphoid and nonlymphoid tissues (metastatic lymph nodes soft tissue/visceral metastases, respectively) were collected from stage III/IV melanoma patients investigated for presence function specific differentiation antigen Melan-A/MART-1. Comparative analysis was...
The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising approach to the immunotherapy cancer. A phase I study was conducted test feasibility, safety, and survival adoptively transferred Melan-A-specific CTL lines melanoma patients.Eleven HLA-A2+ patients with metastatic received at least three intravenous infusions 2-week intervals. were by four rounds stimulation purified CD8+ peripheral blood autologous dendritic cells pulsed an...
Oral anticancer drugs (eg, kinase inhibitors) play an important role in cancer therapy. However, considerable challenges regarding medication safety of oral have been reported. Randomized, controlled, multicenter studies on the impact intensified clinical pharmacological/pharmaceutical care patient and treatment perception are lacking.Patients were eligible for randomized, AMBORA study, if they newly started any approved 2001 or later without restriction to certain tumor entities. Patients...
Abstract Adoptive T cell therapy has been successfully used for treatment of viral and malignant diseases. However, little is known about the fate trafficking transferred Ag-specific cells. Using tetramer (TM) technology which allows detection quantification CTL, we assessed frequency circulating Melan-A-specific CTL in advanced melanoma patients during adoptive therapy. were generated from HLA-A2.1+ by vitro stimulation CD8+ cells with dendritic pulsed a mutated HLA-A2-binding Melan-A...
Abstract With the increasing use of innovative next generation sequencing (NGS) platforms in routine diagnostic and research settings, genetic landscape uterine sarcomas has been dynamically evolving during last two decades. Notably, majority recently recognized genotypes represent gene fusions, while recurrent oncogene mutations and/ or therapeutic value have rare. Recently, a distinctive aggressive sarcoma expressing S100 SOX10, but otherwise lacking morphological, immunophenotypic...
JBT 1001 is a vaccine used for therapy of prostate cancer (CA), which consists recombinant prostate-specific antigen (PSA) with lipid A formulated in liposomes. Patients CA were vaccinated emulsified mineral oil (n = 5) or the combination granulocyte-macrophage colony-stimulating factor (GM-CSF) administered locally at site vaccination 5). Frequency PSA-reactive T cells was measured peripheral blood mononuclear (PBMC) before and after immunization, using an interferon-gamma (IFN-gamma)...
Small blue round cell sarcomas (SBRCSs) are a heterogeneous group of tumors with overlapping morphologic features but markedly varying prognosis. They characterized by distinct chromosomal alterations, particularly rearrangements leading to gene fusions, whose detection currently represents the most reliable diagnostic marker. Ewing (ESs) common SBRCSs, defined fusions involving EWSR1 and transcription factors ETS family, while frequent non-EWSR1-rearranged SBRCSs harbor CIC rearrangement....
Local ablative therapies (LAT) are increasingly used in patients with metastatic soft tissue sarcoma (STS), yet evidence-based standards lacking. This study aimed to assess the impact of LAT on survival STS and identify prognostic factors.
Genetic differences between humans and in vivo model systems, including mice nonhuman primates, make it difficult to predict the efficacy of immunoglobulin G (IgG) activity understand molecular cellular mechanisms underlying that activity. To bridge this gap, we established a small-animal system allowed us study human IgG effector functions context an intact immune without interference murine Fcγ receptors expressed on mouse innate cells vivo. Using B cell depletion with different variants...
The prospective multicentre Phase II PTLD-2 trial (NCT02042391) tested modified risk-stratification in adult SOT recipients with CD20-positive PTLD based on principles established the PTLD-1 trials: sequential treatment and risk-stratification. After rituximab monotherapy induction, patients complete remission as well those partial IPI < 3 at diagnosis (low-risk) continued thus chemotherapy free. Most others (high-risk) received R-CHOP-21. Thoracic who progressed (very-high-risk) alternating...
Abstract Tumor-reactive T cells play an important role in cancer immunosurveillance. Applying the multimer technology, we report here unexpected high frequency of Melan-A–specific CTLs a melanoma patient with progressive lymph node metastases, consisting 18 and 12.8% total peripheral blood tumor-infiltrating CD8+ cells, respectively. revealed cytolytic activity against allogeneic Melan-A–expressing target but failed to kill autologous tumor cells. Loading Melan-A peptide reversed resistance...
Human monocyte-derived dendritic cells (DC) can ingest apoptotic tumor (ATC) and present tumor-associated antigens (TAA) to T cells, leading the generation of tumor-specific cytotoxic effector (Cancer Res 2000;60:3542–9). To further augment antitumor cell responses, attempts were made modify antigen presentation cross-priming by DC fed with ATC. Proinflammatory cytokines (PC), CD40 ligand (CD40L) and/or interferon-γ (IFN-γ) found markedly enhance immunogenicity TAA presented DC. While PC...
<b><i>Background</i></b>: Childhood cancer survivors are at risk for therapy-related sequelae and, therefore, require long-term follow-up. At 2 university hospitals in Germany collaborative multidisciplinary late effects clinics were installed to provide specialized care and evaluate the current health status of these patients a clinical setting. <b><i>Patients and</i></b><b><i>Methods</i></b>: Every patient who visited...
Abstract Alterations in Homologous Recombination Repair (HRR) Pathway genes have been found to be associated with HR‐Deficiency (HRD), which is an approved biomarker for PARP Inhibitor (PARPi) treatment. The aim of a Molecular Tumor Board (MTB) identify molecular alterations cancer patients advanced tumors that may suggest off‐label treatment options. So far, few studies analyzed the presence HRR gene mutations and their association HRD outside clinical studies. Currently, no data on testing...
Anaemia is a frequent, clinically relevant condition in various chronic diseases. It seems also to be prevalent patients with respiratory failure (CRF). We studied the characteristics of anaemia CRF and its associations clinical outcome.In prospective design, 271 consecutive were evaluated; other conditions often associated excluded. Haematological laboratory physiological parameters, health-related quality life (HRQL), dyspnoea 48-month survival determined. was defined according WHO...